Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Total Debt: 2020-2025

Historic Total Debt for Cellebrite DI (CLBT) over the last 5 years, with Sep 2025 value amounting to $7.5 million.

  • Cellebrite DI's Total Debt rose 315.38% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 315.38%. This contributed to the annual value of $7.0 million for FY2024, which is 26.09% up from last year.
  • Cellebrite DI's Total Debt amounted to $7.5 million in Q3 2025, which was up 9.60% from $6.9 million recorded in Q2 2025.
  • Cellebrite DI's Total Debt's 5-year high stood at $9.5 million during Q4 2021, with a 5-year trough of -$3.3 million in Q3 2022.
  • Moreover, its 3-year median value for Total Debt was $1.8 million (2024), whereas its average is $3.3 million.
  • Its Total Debt has fluctuated over the past 5 years, first plummeted by 1,838.56% in 2022, then spiked by 974.63% in 2025.
  • Quarterly analysis of 5 years shows Cellebrite DI's Total Debt stood at $9.5 million in 2021, then tumbled by 43.44% to $5.4 million in 2022, then grew by 2.24% to $5.5 million in 2023, then rose by 26.09% to $7.0 million in 2024, then surged by 315.38% to $7.5 million in 2025.
  • Its Total Debt stands at $7.5 million for Q3 2025, versus $6.9 million for Q2 2025 and $6.6 million for Q1 2025.